Stereoisomers and analogues of amastatin, [(2S, 3l?)-3-amino-2-hydroxy-5-methylhexanoyl]-LVal-L-Val-L-Asp, were synthesized and their inhibitory activities towards aminopeptidase A (AP-A) and other arylamidases tested. Amongthe four stereoisomers of a newamino acid residue in amastatin, the 25 stereoisomers exhibited strong activity. In a series of compounds in which the Cterminal amino acid of amastatin was substituted by other amino acids, the one containing Asp or Glu showed the strongest activity towards AP-A. In a series of compoundsin which the second or third residue from the amino terminal of amastatin was substituted by other amino acids, the one containing hydrophobic amino acids showed strong activity. In the study of the relationship of the length of the peptide chain and inhibitory activity, the activity towards AP-Awas seen to increase until the length of the peptide reached that of a tetrapeptide.
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The structure of amastatin is [(2S,3R)-3-amino-2-hydroxy-5-methylhexanoyl]-LVal-L-Val-L-Asp. 2) We synthesized stereoisomers of amastatin and related compounds and studied structure-activity relationships.
Syn thesis
The method employed for the synthesis of (2S,3R)X and (2R,3R)X was as described previously.^In the same way, (2R,3S)X and (2S,3S)X were prepared from L-leucine. Other analogues were prepared using Z-glycine as a starting material in the same way. Resolution of the diastereoisomeric mixture of (2S,3R)X and (2R,3R)X was achieved by Dowex-50W column chromatography.2) (2R,3S)X and (2S,3S)X were separated by the same method. 7V-Benzyloxycarbonyl-X and its analogues * Present address: Central Research Laboratories, Sanraku-Ocean Co., Ltd., Johnan, Fujisawa, Kanagawa 251, Japan.
Abbreviations: AP-A, aminopeptidase A (EC 3.4.1 1.7); AP-B, aminopeptidase B (EC 3.4.ll.6); Leu-AP, leucine aminopeptidase (EC 3.4. 1 1. 1); Gly-Pro-AP, glycyl-proline dipeptidyl aminopeptidase (EC 3.4.14.1); Gly-Pro-Leu-AP, glycyl-prolyl-leucine tripeptidyl aminopeptidase; Gly-His-Lys-AP, glycyl-histidyl-lysine tripeptidyl aminopeptidase; NA, group and the free carboxyl group are important. The role of the hydroxyl group is suggested by the activity of different stereoisomers as will be discussed later. (2S,3R)X itself showed no inhibitory activity. Bryce and Rabin3) proposed the reaction mechanism for Leu-AP. We speculated that the inhibition mechanism of amastatin from their report was as shown in Scheme I. Amastatin shows strong inhibition of Leu-AP as well as AP-A. Binding of amastatin to the active site of these enzymes is suggested by the competitive nature of the inhibition. The Nterminal amino group of the substrate corresponds to the amino group at C3 of (2S,3^)X of amastatin, but the configuration of the N-terminal amino acid of the natural substrate is S while the configuration at C3 of X is R. To clarify the importance of the configuration of X, the four stereoisomers were prepared and tested for inhibition of arylamidases. The results shown in Table II indicate that the configuration at C2, but not C3, is a very important factor for the manifestation of the activity. The fact that the S configuration at C2 is essential for the enzyme inhibiting activity suggests that in the enzymatic reaction the amino and hydroxyl groups chelate to metal of the enzyme more strongly than substrate. The metal contained in AP-A4) is speculated to be Zn2+ because microvillar peptidases6' 7) including Leu-AP, AP-B and aminopeptidase Mare Zn2 +-enzymes.
Amastatin-related compounds in which the C-terminal L-aspartic acid moiety is substituted by other amino acids are shown in Table  III . The compound containing L-aspartic acid (natural one) showed the strongest activity and those containing neutral or basic aminoacids tended to show less activity towards AP-A. It is noteworthy that X-Val-Val-Pro (8) strongly inhibits Gly-Pro-Leu-AP and Gly-His-Lys-AP.
Amastatin-related compounds in which the second or third residue from the amino terminal of amastatin is substituted by other amino acids are shown in Table IV . Among the compounds, those containing hydrophobic amino acids, such as valine or leucine, showed strong activity towards AP-A. In order to inhibit Leu-AP strongly, hydrophobic amino Gly-His-Lys-AP were inhibited weakly by the synthetic peptides (13, 9) which had l-G1u as the second or third residue from the amino end of amastatin.
The activity of amastatin-related compounds in which the iso-buty\ group of (2S,3R)X is substituted by hydrogen and benzyl groups is shown in Table V . The derivative with a substituted benzyl group show- The study of the relationship of the length of the peptide chain and activity makes it clear that a tetrapeptide has the strongest activity towards AP-A. These data are shown in Table   VI . These results indicate that the distance between terminal amino and carboxyl groups is important for the inhibitory activity towards AP-A. However, inhibitors of each aminopeptidase differ in the suitable length of the peptide chain for strong inhibitory activity. Tables II~VI show that amastatin and its analogues inhibit many arylamidases other than Gly-Pro-AP. AP-A, AP-B and Leu-AP which were inhibited by amastatin are metalloenzymes,5) while Gly-Pro-AP is a serineenzyme.6) It was speculated, as shown in Scheme 1, that amastatin and its analogues formed amastatin-Zn2 +-enzyme complexes in the active centers of AP-A, AP-B and Leu-AP.
On the other hand, amastatin is thought to be unable to bind to Gly-Pro-AP because of a lack of M2+in the active center. OBzl-2Tos, Pro-OBzl HC1, Z-Leu 1/2 piperazine salt, ZGly, DCC, HOBt and TFA were purchased from the Protein Research Foundation, Japan. Val-OBzl Tos was purchased from Sigma Co., Ltd., U.S.A. CBZ-S reagent and DMPwere purchased from Kokusan Chemical Co., Ltd., and Wako Pure Chemical Industries, Ltd., Japan, respectively. Dowex-50W x 4 (200~400 mesh) and Avicel were purchased from Dow Chemical Co., Ltd., and Funakoshi Pharmaceutical Co., Ltd., Japan, respectively. AP-A, AP-B, Gly-Pro-AP, Gly-Pro-Leu-AP and GlyHis-Lys-AP were purified according to the methods of Nagatsu et al. Nippon Kayaku Co., Ltd., Japan.
Determination of the inhibitory activity. All the enzyme sources and substrates which were employed for testing of the inhibitory activity of amastatin and amastatin analogues are shown in fable I. The assay method for the activity of AP-A and Leu-AP is described in ref.
1. The activity of the other arylamidases was assayed by the same method as for AP-A and Leu-AP, that is, the assay system contained the following components in a total volume of NaHPO4, 0.06g KH2PO4, 0,1 g MgSO4 and 1.0g glucose in 1 liter adjusted to pH 7.2 by addition of NaHCO3). After 3 min preincubation at 37°C, the reaction was initiated by addition of the enzyme solution. Exactly 30 min later, the reaction was stopped by adding 1 ml of a solution of Fast Garnet GBC (lmg/ml) in 1m acetate buffer (pH 4.2), containing 10% Tween 20. After 20 min at room temperature, absorbance was measured at 525 nm. The reaction was also carried out without addition of the enzyme solution and the result was taken as the blank. The concentration (/xg/ml or m) of amastatin or amastatin analogues required for 50% inhibition (IC50) was calculated.
General synthetic procedure for Z-amino acid 3,5-dimethylpyrazolide.
Z-Amino acid (10 mmol) and DMP (12 mmol) were treated with DCC(10 mmol) in CH2C12 (200ml) at 0°C for 1hr and then at room temperature overnight. After removal of DCU, the solvent was evaporated. The solid residue was dissolved in CH2C12(100ml) and crystallized from EtOAc-petroleum ether. The Zamino acid-DMP products (24~26) thus obtained are summarized in Table VII. Synthetic procedure for X and its analogues. To a suspension of LiAlH4 (20 mmol) in THF (200ml) was added a solution ofZ-amino acid-DMP (10 mmol) in THF (200 ml) over a period of 1 hr, keeping the temperature at -20°to -25°C. After removal of A1(OH)3 by centrifugation, the supernatant was obtained. The solvent was evaporated. The residue was dissolved in Et2O, washed with H2O, and then evaporated. To the oily residue was added an ice-cold solution of NaHSO3 (7~8 mmol) and the mixture was stirred at room temperature overnight. tOAc (200ml) and NaCN aqueous solution (7~8 mmol in 50ml) and the reaction mixture was stirred for 3~4 hr at room temperature. The EtOAcphase was washed with H2Oand then evaporated to give the cyanohydrin as an oil. This was hydrolyzed in dioxane-concentrated HC1 (1 : 1, 100ml) by refluxing (12hr).
The hydrolyzate was dried after washing with EtOAc. The aqueous reaction mixture was adsorbed on a Dowex-50W(H+) column followed by elution with 1 n NH4OH.The eluate was dried and then washed with acetone giving a colorless powder of a mixture of (2R,3R)X and (2S,3R)X. The powder was dissolved in 0.1 m pyridine-formic acid buffer (pH 3.1) and applied to a Dowex-50Wcolumn equilibrated with the same buffer. (2S,3R)X was eluted later than its diastereoisomer. When the separation was incomplete, further purification was done by cellulose column chromatography using EtOAc-pyridine-AcOH-H2O (7: 1 : 1 : 1, v/v). (2R,3R)X and (2S,3R)X were crystallized from nPrOH-H2O.
(2R,3S)X (27c) and (2S,3S)X (27d) were synthesized from L-Leu in the same manner as (2S,3R)X (27a) and (2R,3R)X (27b) were from D-Leu. The physicochemical properties of 27a~27d are summarized in Table VIII. 3-Amino-2-hydroxy-propionic acid (28) was synthesized from Z-Gly in the same manner. The method of synthesis of (2S,3/Q-3-amino-2-hydroxy-4-phenylbutanoic acid (29) was as described by Nishizawa et al.12) (Table IX) .
The yield and properties of the Z-X stereoisomers (0 06 mmol). After the synthetic peptides were purified by crystallization with benzene-EtOAc, the protecting groups (Z and Bzl groups) of the peptides were removed by hydrogenolysis using palladium-charcoal as catalyst to yield amastatin analogues. The physicochemical properties of the synthetic peptides (1~23) are summarized in Table XII . The structure of the synthetic peptides was confirmed by elementary analysis, PMR, IR and mass spectra
